We also demonstrated that that sorted cancer cells were able to grow in vitro and in vivo. One of the advantages is that the tumor cells start to grow significantly

earlier in NOG-EGFP mice than in NOD/SCID mice. Our present results provide a novel way of employing of collected cancer cells eFT-508 for to various subsequent analyses. In the report of the NOD/SCID EGFP xenografts, cancer cells labeled with another type of fluorescence were used for the separation study [6]. The present study suggests that fluorescent labeling of cancer cells is not necessary for the separation of cancer cells and host cells. On the other hand, this method is applicable for the collection of not only cancer cells but also stromal cells. The methodology using fluorescent mouse xenografts might usefully contribute to studies of cancer stromal cells. In conclusion, NOG-EGFP has high potential utility for complete separation of cancer cells and stromal cells with minimal mTOR inhibitor contamination, if any, from xenografted tumors. Further studies are needed to establish a solid methodology for the separation and collection of stromal/cancer cells, and the use of NOG-EGFP mice for this is very promising. Grant Support This work was supported by Japan Society for the

Promotion of Science Grant-in-Aids for Young Scientists (B: 23791512) (HH), (B: 23791515) (TO), (B: 23791514) (MM). References 1. Garber K: From human to mouse and back: ‘tumorgraft’ models surge in popularity. J Natl Cancer Inst. 2009,

101:6–8.PubMedCrossRef 2. Walter K, Eshleman J, Goggins M: Xenografting and harvesting human ductal pancreatic adenocarcinomas for DNA analysis. Methods Mol Med. 2005, 103:103–111.PubMed 3. Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al.: A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011, 10:1311–1316.PubMedCrossRef 4. Hahn SA, Seymour AB, Hoque AT, et al.: Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 1995, 55:4670–4675.PubMed find more 5. Machida K, Suemizu H, Kawai K, et al.: Higher susceptibility of NOG mice to xenotransplanted tumors. J Toxicol Sci 2009, 34:123–127.PubMedCrossRef 6. Niclou SP, Danzeisen C, Eikesdal HP, et al.: A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. FASEB J 2008, 22:3120–3128.PubMedCrossRef 7. Suemizu H, Yagihashi C, Mizushima T, et al.: Establishing EGFP congenic mice in a NOD/Shi-scid IL2Rg(null) (NOG) genetic background using a marker-assisted selection protocol (MASP). Exp Anim 2008, 57:471–477.PubMedCrossRef 8. Euhus DM, Hudd C, LaRegina MC, Johnson FE: Tumor measurement in the nude mouse. J Surg Oncol 1986, 31:229–234.PubMedCrossRef 9. Yang M, Reynoso J, Jiang P, Li L, Moossa AR, Hoffman RM: Transgenic nude mouse with ubiquitous green fluorescent protein expression as a host for human tumors.